Q3 2024 Earnings Summary
| Metric | YoY Change | Reason |
|---|---|---|
Total Revenue | +5% | Stronger U.S. dialysis volume and growth in integrated kidney care services boosted revenue, despite higher labor costs due to inflation. These trends are expected to continue supporting organic growth. |
U.S. Dialysis | +4% | Driven by increased treatment volume, slight improvements in reimbursement rates, and acquired treatment growth, although labor cost pressures remain a challenge for margins. |
Operating Income | +8% | Top-line expansion coupled with cost discipline improved year-over-year margins, offset partially by inflationary wage pressures; DaVita continues to optimize center operations to sustain profitability. |
Net Income | +137% | A substantial jump due to improved operating performance, lower restructuring charges, and ongoing cost optimization measures, further enhanced by share repurchases. |
Interest Expense | +39% | Higher rates on floating-rate debt and increased borrowing drove interest costs up, prompting DaVita to explore refinancing opportunities to mitigate future interest burdens. |
EPS (Basic) | -5% | Although net income rose, EPS declined year-over-year due to share count changes, interest expense, and share-based compensation, indicating that future buybacks and strong operating trends may offset these factors. |
| Metric | Period | Previous Guidance | Current Guidance | Change |
|---|---|---|---|---|
Adjusted Operating Income (OI) | FY 2024 | $1.91B to $2.01B | $1.91B to $2.01B | no change |
Adjusted EPS | FY 2024 | $9.25 to $10.05 | $9.25 to $10.05 | no change |
Revenue Per Treatment (RPT) Growth | FY 2024 | 50 to 100 basis points | 3.5% to 4% | raised |
Treatment Volume Growth | FY 2024 | no prior guidance | 0.5% to 1% | no prior guidance |
Free Cash Flow (FCF) | FY 2024 | no prior guidance | $950M to $1.2B | no prior guidance |
IKC Operating Loss | FY 2024 | no prior guidance | $50M | no prior guidance |
Hurricane-Related Q4 2024 OI | FY 2024 | no prior guidance | $10M to $20M | no prior guidance |
Leverage Ratio | FY 2024 | no prior guidance | 3x to 3.5x EBITDA | no prior guidance |
| Topic | Previous Mentions | Current Period | Trend |
|---|---|---|---|
Elevated mortality rates | Major headwind across prior quarters, cited as non-structural but a key factor limiting growth | Continues to weigh on volume growth, expected to persist into 2025 | Remains a central concern impacting volumes |
Treatment volume growth | Below pre-COVID trends, affected by elevated mortality, weather disruptions, and clinic closures | Reaffirmed 0.5%–1% for 2024; flat in Q3 due to mortality, minor hurricane impact | Continues to lag; cautious outlook |
Revenue per treatment (RPT) | Raised guidance to 3.5%–4% in Q2; previously 2.5%–3%, driven by better collections, payer mix, and contract negotiations | Up over $4 sequentially; guided 3.5%–4% for 2024; likely lower but above historical in 2025 | Strong growth momentum, slightly tempered for next year |
Adjusted operating income | Guidance increased multiple times, reflecting strong RPT offset by volume challenges | Reaffirmed $1.91–$2.01B for 2024, includes Baxter disruption impact | Stays robust within updated range |
Supply chain disruptions | No prior mention | Baxter facility closure disrupted PD solutions; $10–$20M Q4 impact | New challenge introduced in Q3 2024 |
Integration of oral drugs | CMS confirmed intent in Q2 2024; DaVita supports earlier integration | Mandated for 2025; uncertainty in reimbursement rates, potential wide financial swing | Ongoing transition with open financial variables |
Hurricanes and extreme weather | Q2 hurricanes caused 20 bps impact | Hurricanes Helene & Milton caused 10 bps volume headwind; supply chain further stressed | Recurring disruptions, largely managed |
IKC segment losses | Continuing losses, with aims for breakeven by 2026 | On track for $50M loss in 2024; stable vs. guidance | Consistent with previous outlook |
Center capacity utilization | At 58%–59% in prior periods, below pre-COVID 65% | Not discussed in Q3 | No current update |
Cost per treatment management | Flat to slightly lower; balanced by labor, inflation, and productivity gains | Increased $2 QoQ from labor and benefits | Small rise; still closely monitored |
-
Volume Growth & Mortality
Q: What are volume growth expectations amid elevated mortality?
A: The company expects 2024 volume growth of 50 to 100 basis points , and for 2025, a base growth of 75 basis points, adjusted down by 25 basis points, resulting in a 50 basis points starting point. Elevated mortality remains the main factor impacting future growth, despite healthy admissions and stable patient mix. -
Revenue per Treatment Outlook
Q: Will elevated RPT growth continue into next year?
A: The company anticipates Revenue per Treatment (RPT) growth will be lower than the 3.5% to 4% seen this year but still higher than historical ranges. While RPT is expected to be above normal next year, it will not match the elevated levels of 2024. -
Phosphate Binders Financial Impact
Q: What is the impact of phosphate binders inclusion next year?
A: The financial impact of including phosphate binders into the bundle next year is uncertain due to unknown government reimbursement rates, product mix, pricing differences between branded and generic drugs, and potential volume changes. The company cannot provide a useful range yet but expects more information next quarter. -
Baxter PD Supply Issues
Q: How will Baxter's PD supply issues affect patients?
A: Due to Baxter's peritoneal dialysis supply issues, the company expects a decline in home dialysis mix in the next quarter but plans to normalize by the first quarter. They anticipate keeping the vast majority of PD patients, with minimal loss to other providers. -
Interest Expense Impact
Q: Will interest expense rise further into 2025?
A: Interest expense of $135 million per quarter is expected to remain stable, potentially decreasing slightly next year due to lower interest rate caps. The company does not anticipate incurring more debt in the near term. -
Increased G&A Expenses
Q: Why did G&A expenses increase this quarter?
A: The 7% sequential and 10% year-over-year increase in G&A expenses was driven by investments in IT, wage increases, and reimbursement operations to support the rise in revenue per treatment. -
2025 Headwinds and Tailwinds
Q: How will headwinds and tailwinds affect 2025 earnings?
A: The company expects headwinds and tailwinds to largely offset each other at the operating income line in 2025. Factors include elevated mortality, clinic closures, PD supply issues, and reimbursement changes, which could balance out. -
IKC Performance Expectations
Q: How is IKC performing and what's expected?
A: The Integrated Kidney Care (IKC) is on track for the year, reaffirming a negative $50 million impact for 2024. The company suggests evaluating IKC on an annual basis due to quarterly volatility. -
Commercial Mix Trends
Q: What are the trends in commercial mix?
A: There were no material changes in commercial mix this quarter. The company is underrepresented in Qualified Health Plans (QHPs), with a 3% mix compared to the market's 7–8%. They are growing at the same rate as the market in QHPs. -
Hurricane Impacts on EBITDA
Q: How did hurricanes impact EBITDA this quarter?
A: Hurricanes had an impact of about $10 million to $20 million on EBITDA, mainly due to increased mistreatment rates. The storms added an additional 10 basis points to mistreatment rates in Q3.
Research analysts covering DAVITA.